Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe

International Journal of Drug Policy

Volumn 24, Issue 2, 2013, Pages 85-100

  Palmateer, Norah E ^a   Hutchinson, Sharon J ^a,b   Innes, Hamish ^a,b   Schnier, Christian ^a,b   Wu, Olivia ^c   Goldberg, David J ^a   Hickman, Matthew ^d  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Hepatitis C; Injecting drug use; Meta analysis; Needle sharing; Review

Indexed keywords

BIOLOGICAL MARKER;

COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG ABUSE; EUROPE; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LONGITUDINAL STUDY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK FACTOR; SELF REPORT; SYRINGE NEEDLE;

EUROPE; HEPATITIS C; HUMANS; INCIDENCE; NEEDLE SHARING; PREVALENCE; RISK FACTORS; RISK-TAKING; SELF REPORT; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84875382061     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2012.08.006     Document Type: Review

References (58)

1. Aitken C.K., McCaw R.F., Bowden D.S., Tracy S.L., Kelsall J.G., Higgs P.G., et al. Molecular epidemiology of hepatitis C virus in a social network of injection drug users. Journal of Infectious Diseases 2004, 190(9):1586-1595.
2. Amarapurkar D. Natural history of hepatitis C virus infection. Journal of Gastroenterology and Hepatology 2000, 15(Suppl):E105-E110.
3. Burt R.D., Thiede H., Hagan H. Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users. Drug and Alcohol Dependence 2009, 105(3):215-220.
4. Carvell A.L., Hart G.J. Risk behaviours for HIV infection among drug users in prison. British Medical Journal 1990, 300(6736):1383-1384.
5. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359-362.
6. Cook P.A., McVeigh J., Syed Q., Mutton K., Bellis M.A. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction 2001, 96(12):1787-1797.
7. Craine N., Hickman M., Parry J.V., Smith J., Walker A.M., Russell D., et al. Incidence of hepatitis C in drug injectors: The role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection 2009, 137(9):1255-1265.
8. Craine N., Walker A.M., Williamson S., Brown A., Hope V.D. Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Communicable Disease and Public Health 2004, 7(3):216-219.
9. Crofts N., Caruana S., Bowden S., Kerger M. Minimising harm from hepatitis C virus needs better strategies. British Medical Journal 2000, 321(7265):899.
10. Darke S., Hall W., Heather N., Ward J., Wodak A. The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS 1991, 5(2):181-185.
11. De P., Roy E., Boivin J.F., Cox J., Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: A systematic and methodological review. Journal of Viral Hepatitis 2008, 15(4):279-292.
12. De Irala J., Bigelow C., McCusker J., Hindin R., Zheng L. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. American Journal of Epidemiology 1996, 143(7):725-732.
13. Denis B., Dedobbeleer M., Collet T., Petit J., Jamoulle M., Hayani A., et al. High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the " cotton-filter" in transmission: The GEMT Study. Acta Gastroenterologica Belgica 2000, 63(2):147-153.
14. Des Jarlais D.C., Paone D., Milliken J., Turner C.F., Miller H., Gribble J., et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: A quasi-randomised trial. Lancet 1999, 353:1657-1661.
15. Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology 2008, 48(1):148-162.
16. Foley S., Abou-Saleh M.T. Risk behaviors and transmission of Hepatitis C in injecting drug users. Addictive Disorders and Their Treatment 2009, 8(1):13-21.
17. Galeazzi B., Tufano A., Barbierato E., Bortolotti F. Hepatitis C virus infection in Italian intravenous drug users: Epidemiological and clinical aspects. Liver 1995, 15(4):209-212.
18. Girardi E., Zaccarelli M., Tossini G., Puro V., Narciso P., Visco G. Hepatitis C virus infection in intravenous drug users: Prevalence and risk factors. Scandinavian Journal of Infectious Diseases 1990, 22(6):751-752.
19. Goldstein M.F., Friedman S.R., Neaigus A., Jose B., Ildefonso G., Curtis R. Self-reports of HIV risk behavior by injecting drug users: Are they reliable?. Addiction 1995, 90(8):1097-1104.
20. Hagan H., Des Jarlais D.C., Stern R., Lelutiu-Weinberger C., Scheinmann R., Strauss S., et al. HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. International Journal of Drug Policy 2007, 18(5):341-351.
21. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases 2011, 204(1):74-83.
22. Hahn J.A., Page-Shafer K., Ford J., Paciorek A., Lum P.J. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug and Alcohol Dependence 2008, 93(1-2):43-50.
23. Hedouin V., Gosset D. Infection with hepatitis C virus in a prison environment. A prospective study in Loos-lez-Lille, France. Gastroenterologie Clinique et Biologique 1998, 22(1):55-58.
24. Hellard M.E., Aitken C.K., Hocking J.S. Tattooing in prisons--not such a pretty picture. American Journal of Infection Control 2007, 35(7):477-480.
25. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21(11):1539-1558.
26. Holbach M., Frosner G.G., Donnerbauer E., Dittmeier E., Holbach B. Prevalence of Hepatitis A, B, and C markers and risk factors for infection in patients having used intravenous drugs. Sucht 1998, 44(6):S390-S398.
27. Huntington S., Folch C., Gonzalez V., Merono M., Ncube F., Casabona J. Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia. Enfermedades Infecciosas y Microbiologia Clinica 2010, 28(4):236-238.
28. Jose B., Friedman S.R., Neaigus A., Curtis R., Grund J.P., Goldstein M.F., et al. Syringe-mediated drug-sharing (backloading): A new risk factor for HIV among injecting drug users. AIDS 1993, 7(12):1653-1660.
29. Judd A., Hutchinson S., Wadd S., Hickman M., Taylor A., Jones S., et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: Cross sectional analysis. Journal of Viral Hepatitis 2005, 12(6):655-662.
30. Jurgens R., Ball A., Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infectious Diseases 2009, 9(1):57-66.
31. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection 2011, 17(2):107-115.
32. Lelutiu-Weinberger C., Pouget E.R., Des Jarlais D.D., Cooper H.L., Scheinmann R., Stern R., et al. A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups. Social Science and Medicine 2009, 68(3):579-590.
33. Maher L., Li J., Jalaludin B., Chant K.G., Kaldor J.M. High hepatitis C incidence in new injecting drug users: A policy failure?. Australian and New Zealand Journal of Public Health 2007, 31(1):30-35.
34. Malliori M., Sypsa V., Psichogiou M., Touloumi G., Skoutelis A., Tassopoulos N., et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction 1998, 93(2):243-251.
35. Mathei C., Robaeys G., van Damme P., Buntinx F., Verrando R. Prevalence of hepatitis C in drug users in Flanders: Determinants and geographic differences. Epidemiology and Infection 2005, 133(1):127-136.
36. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378(9791):571-583.
37. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews. Addiction 2010, 105(5):844-859.
38. Perlis T.E., Des Jarlais D.C., Friedman S.R., Arasteh K., Turner C.F. Audio-computerized self-interviewing versus face-to-face interviewing for research data collection at drug abuse treatment programs. Addiction 2004, 99(7):885-896.
39. Petry N.M. Reliability of drug users' self-reported HIV risk behaviors using a brief, 11-item scale. Substance Use and Misuse 2001, 36(12):1731-1747.
40. Platt L., Sutton A.J., Vickerman P., Koshkina E., Maximova S., Latishevskaya N., et al. Measuring risk of HIV and HCV among injecting drug users in the Russian Federation. European Journal of Public Health 2009, 19(4):428-433.
41. Pouget E.R., Hagan H., Des Jarlais D.C. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2011, (epub ahead of print).
42. Rezza G., Sagliocca L., Zaccarelli M., Nespoli M., Siconolfi M., Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scandinavian Journal of Infectious Diseases 1996, 28(1):27-29.
43. Roy K., Hay G., Andragetti R., Taylor A., Goldberg D., Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: A review of the literature. Epidemiology and Infection 2002, 129(3):577-585.
44. Sanchez V.M., Castro V.F., Alvarez J.R.P., Herrero L.E.A., Honorato M.A., Gonzalez M.J.C., et al. Seroprevalence of hepatitis C virus infection at the time of entry to prison in the prison population in the north-east of Spain. Revista Espanola de Salud Publica 1998, 72(1):43-51.
45. Serfaty M.A., Lawrie A., Smith B., Brind A.M., Watson J.P., Gilvarry E., et al. Risk factors and medical follow-up of drug users tested for hepatitis C--can the risk of transmission be reduced?. Drug and Alcohol Review 1997, 16(4):339-347.
46. Sherriff L.C.H., Mayon-White R.T. A survey of hepatitis C prevalence amongst the homeless community of Oxford. Journal of Public Health Medicine 2003, 25(4):358-361.
47. Stark K., Muller R., Bienzle U., Guggenmoos-Holzmann I. Frontloading: A risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS 1996, 10(3):311-317.
48. Stark K., Schreier E., Muller R., Wirth D., Driesel G., Bienzle U. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scandinavian Journal of Infectious Diseases 1995, 27(4):331-337.
49. Sterne J.A., Sutton A.J., Ioannidis J.P., Terrin N., Jones D.R., Lau J., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. British Medical Journal 2011, 343:d4002.
50. Taylor A., Fleming A., Rutherford J., Goldberg D. Examining the injecting practices of injecting drug users in Scotland 2004, Scottish Executive Effective Interventions Unit, Edinburgh.
51. Taylor A., Hutchinson S.J., Gilchrist G., Cameron S., Carr S., Goldberg D.J. Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in Glasgow. Harm Reduction Journal 2008, 5(11).
52. Thibault V., Bara J.L., Nefau T., Duplessy-Garson C. Hepatitis C transmission in injection drug users: Could swabs be the main culprit?. Journal of Infectious Diseases 2011, 204(12):1839-1842.
53. Thiede H., Hagan H., Campbell J.V., Strathdee S.A., Bailey S.L., Hudson S.M., et al. Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug and Alcohol Dependence 2007, 91(Suppl 1):S39-S47.
54. Tohme R.A., Holmberg S.D. Is sexual contact a major mode of hepatitis C virus transmission?. Hepatology 2010, 52(4):1497-1505.
55. Tohme R.A., Holmberg S.D. Transmission of hepatitis C virus infection through tattooing and piercing: A critical review. Clinical Infectious Diseases 2012, 54(8):1167-1178.
56. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102(9):1454-1462.
57. Vescio M.F., Longo B., Babudieri S., Starnini G., Carbonara S., Rezza G., et al. Correlates of hepatitis C virus seropositivity in prison inmates: A meta-analysis. Journal of Epidemiology and Community Health 2008, 62(4):305-313.
58. Viswanathan M., Berkman N.D. Development of the RTI item bank on risk of bias and precision of observational studies. Journal of Clinical Epidemiology 2012, 65(2):163-178.